Efficacy of the ATR Inhibitor Ceralasertib in Patients with ARID1A-Deficient Gynecologic and Other Solid Tumor Malignancies
Ceralasertib monotherapy demonstrated promising anti-tumor activity in ARID1A-deficient gynecologic malignancies. Tumor molecular and immune correlates may inform the further development of ATR inhibitors in this patient population.
Authors
- Stefanie Ueda (ORCID: https://orcid.org/0000-0002-4359-0966)
- Jessica A. Van Ziffle
- Jocelyn Chapman (ORCID: https://orcid.org/0000-0002-4260-3016)
- PN Munster
- Simon A. Smith (ORCID: https://orcid.org/0000-0002-3591-3016)
- Michelle L Turski
- Susan Calabrese
- Neel H. Shah (ORCID: https://orcid.org/0000-0002-1186-0626)
- Nguyen Pb
- Edwin Alvarez (ORCID: https://orcid.org/0000-0002-9121-0833)
- Ling Chen (ORCID: https://orcid.org/0009-0008-6671-0204)
- John A. Russell
- Alan Ashworth
- Xiaolin Zhu
- Sarah E. Umetsu
- Suzannah Henderson
- Laura Feeney
- Eric A. Collisson
- Julian Aguilar
- Andrew H. Ko
- Rahul R. Aggarwal
Institutions
- University of California, San Francisco (US)
- AstraZeneca (Singapore) (SG)
- Institute of Human Genetics (PL)
- UCSF Helen Diller Family Comprehensive Cancer Center (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2026-02-13
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-4043
- Primary Topic
- Chromatin Remodeling and Cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00